Xencor Inc (XNCR) 8-K Current Report: March 4, 2026
Filed: March 4, 2026
Health Care
Pharmaceutical PreparationsXencor Inc (XNCR) 8-K current report filed with SEC EDGAR on March 4, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items1 item
- Item 7.01: Regulation FD Disclosure
Xencor Inc 8-K Mar 4, 2026 Event Analysis
Item 7.01 · Regulation FD Disclosure
- • Alexion (AstraZeneca sub) unilaterally stopped U.S. royalty payments on Ultomiris®, disputing obligation under existing license agreement
- • At risk: $100–$120M in aggregate royalties Xencor expected to receive through 2028 on U.S. Ultomiris sales
- • Alexion will continue paying ex-U.S. royalties, limiting but not eliminating ongoing royalty stream
- • Xencor disputes Alexion's position and is "evaluating options" — signals potential litigation over patent/license rights
- • Cash guidance $380M–$400M by end of 2026, with runway into mid-2028, suggesting dispute doesn't threaten near-term solvency
Other Xencor Inc 8-K Filings
Get deeper insights on Xencor Inc
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.